APA (7th ed.) Citation

D, L., L, G., DM, O., JW, K., G, G., A, F., . . . AB, O. (2026). Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): A phase 3 randomised controlled trial. Lancet (London, England), 407(10538), 1513. https://doi.org/10.1016/S0140-6736(26)00462-9

Chicago Style (17th ed.) Citation

D, Lorusso, et al. "Overall Survival with Relacorilant and Nab-paclitaxel in Patients with Platinum-resistant Ovarian Cancer (ROSELLA): A Phase 3 Randomised Controlled Trial." Lancet (London, England) 407, no. 10538 (2026): 1513. https://doi.org/10.1016/S0140-6736(26)00462-9.

MLA (9th ed.) Citation

D, Lorusso, et al. "Overall Survival with Relacorilant and Nab-paclitaxel in Patients with Platinum-resistant Ovarian Cancer (ROSELLA): A Phase 3 Randomised Controlled Trial." Lancet (London, England), vol. 407, no. 10538, 2026, p. 1513, https://doi.org/10.1016/S0140-6736(26)00462-9.